Optimizing fluoropyrimidine therapy: Real‐world impact of <i>DPYD</i> genotype‐based dosing on severe toxicity rates
DPYD genotype-based dosing resulted in comparable incidences of severe fluoropyrimidine-related toxicity between wild-type patients and DPYD variant allele carriers. The updated guideline recommendation on dosing of C.1236G>A and C.2846A>T variant carriers appears adequate from a toxicity perspective. Our findings highlight the need to perform an individual dose titration, especially in C.1236G>A variant carriers.
Authors
- Karin H. Herbschleb
- Ankie M. Harmsze (ORCID: https://orcid.org/0000-0002-3134-6608)
- A. Kan
- Marcel P. H. van den Broek
Institutions
- University of Applied Sciences Utrecht (NL)
- Utrecht University (NL)
- St. Antonius Ziekenhuis (NL)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1002/bcp.70266
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05